Omeros Financial Statements From 2010 to 2024
| 3O8 Stock | EUR 7.19 0.85 10.57% |
Check Omeros financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Omeros' main balance sheet or income statement drivers, such as , as well as many indicators such as . Omeros financial statements analysis is a perfect complement when working with Omeros Valuation or Volatility modules.
Omeros |
Omeros Company Shares Owned By Insiders Analysis
Omeros' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Omeros Shares Owned By Insiders | 4.03 % |
Most of Omeros' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Omeros is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 4.028% of Omeros are shares owned by insiders. This is 73.47% lower than that of the Healthcare sector and 71.59% lower than that of the Biotechnology industry. The shares owned by insiders for all Germany stocks is 60.08% higher than that of the company.
Omeros Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Omeros's current stock value. Our valuation model uses many indicators to compare Omeros value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Omeros competition to find correlations between indicators driving Omeros's intrinsic value. More Info.Omeros is number one stock in return on asset category among its peers. It also is number one stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Omeros' earnings, one of the primary drivers of an investment's value.About Omeros Financial Statements
Omeros stakeholders use historical fundamental indicators, such as Omeros' revenue or net income, to determine how well the company is positioned to perform in the future. Although Omeros investors may analyze each financial statement separately, they are all interrelated. For example, changes in Omeros' assets and liabilities are reflected in the revenues and expenses on Omeros' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Omeros. Please read more on our technical analysis and fundamental analysis pages.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system , and immune-related diseases. The company was incorporated in 1994 and is based in Seattle, Washington. OMEROS CORP operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 236 people.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Omeros Stock
When determining whether Omeros is a strong investment it is important to analyze Omeros' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Omeros' future performance. For an informed investment choice regarding Omeros Stock, refer to the following important reports:Check out the analysis of Omeros Correlation against competitors. For more detail on how to invest in Omeros Stock please use our How to Invest in Omeros guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.